CKS1B and breast carcinoma: Consistent with these observations, we used miRNA inhibitors in MDA-MB-231 breast cancer cells to promote gain of 1q12-21 as well as the amplification and increased expression of CKS1B, which is a drug-resistant oncogene (4, 20, –, 23).